Literature DB >> 30588627

Impact of one-time testing for Trypanosoma cruzi antibodies among blood donors in the United States.

Roger Y Dodd1, Jamel A Groves1, Rebecca L Townsend1, Edward P Notari1, Gregory A Foster1, Brian Custer2, Michael P Busch2, Susan L Stramer1.   

Abstract

BACKGROUND: US blood donors are tested for Trypanosoma cruzi antibodies only at their first presentation, based on studies, reviewed here, demonstrating the absence of incident infections. Reports of autochthonous human transmissions of the parasite in Texas have raised concern about the safety of one-time testing.
METHODS: Positive donation frequencies were evaluated among first-time blood donations from 2007 to 2015. Rates and their temporal changes were evaluated in an area of high T. cruzi infection and compared with rates elsewhere. Donors with positive results were surveyed for risk factors and relevant demographic characteristics.
RESULTS: Data from 9.1 million first-time donations were analyzed; 585 (1:15,544) were confirmed positive by radioimmunoprecipitation assay (RIPA) or concordantly positive with a second screening test/licensed assay. Seroprevalence in first-time donors in Southern California (an area of high endemicity) was 1:2,747, or 5.7-fold higher than the overall rate. Rates did not change over time nationally but showed a nonsignificant consistent downward trend in Southern California. The majority (92%) of donors who responded to a questionnaire had one or more T. cruzi endemic-area risk factors. Five donors with likely autochthonous infection were identified (2007-2013); nine additional donors had RIPA false positivity.
CONCLUSION: T. cruzi seroprevalence among donors nationally and in an area of high enzootic infection were stable or declining. Almost all interviewed seropositive donors had known risk factors indicating likely infection years earlier while residing in T. cruzi-endemic areas. In the United States, there was no evidence of increased T. cruzi prevalence among first-time donors.
© 2018 AABB.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30588627     DOI: 10.1111/trf.15118

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  8 in total

Review 1.  Chagas Disease in the United States: a Public Health Approach.

Authors:  Caryn Bern; Louisa A Messenger; Jeffrey D Whitman; James H Maguire
Journal:  Clin Microbiol Rev       Date:  2019-11-27       Impact factor: 26.132

2.  Evaluation of matrix effects and prolonged storage on Trypanosoma cruzi serology in blood donor specimens.

Authors:  Jeffrey D Whitman; Rebecca L Townsend; Caryn Bern; Susan L Stramer
Journal:  Transfusion       Date:  2020-03-12       Impact factor: 3.157

Review 3.  Critical analysis of Chagas disease treatment in different countries.

Authors:  Fernanda de Souza Nogueira Sardinha Mendes; Jose Antonio Perez-Molina; Andrea Angheben; Sheba K Meymandi; Sergio Sosa-Estani; Israel Molina
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-07-08       Impact factor: 2.747

Review 4.  Worldwide Control and Management of Chagas Disease in a New Era of Globalization: a Close Look at Congenital Trypanosoma cruzi Infection.

Authors:  Carmen Muñoz; Montserrat Gállego; Alba Abras; Cristina Ballart; Anna Fernández-Arévalo; María-Jesús Pinazo; Joaquim Gascón
Journal:  Clin Microbiol Rev       Date:  2022-03-03       Impact factor: 50.129

5.  Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026).

Authors:  Chintamani Atreya; Simone Glynn; Michael Busch; Steve Kleinman; Edward Snyder; Sara Rutter; James AuBuchon; Willy Flegel; David Reeve; Dana Devine; Claudia Cohn; Brian Custer; Raymond Goodrich; Richard J Benjamin; Anna Razatos; Jose Cancelas; Stephen Wagner; Michelle Maclean; Monique Gelderman; Andrew Cap; Paul Ness
Journal:  Transfusion       Date:  2019-05-29       Impact factor: 3.157

6.  Chagas Disease Serological Test Performance in U.S. Blood Donor Specimens.

Authors:  Jeffrey D Whitman; Christina A Bulman; Emma L Gunderson; Amanda M Irish; Rebecca L Townsend; Susan L Stramer; Judy A Sakanari; Caryn Bern
Journal:  J Clin Microbiol       Date:  2019-11-22       Impact factor: 5.948

Review 7.  The Oxidative Stress and Chronic Inflammatory Process in Chagas Disease: Role of Exosomes and Contributing Genetic Factors.

Authors:  Edio Maldonado; Diego A Rojas; Fabiola Urbina; Aldo Solari
Journal:  Oxid Med Cell Longev       Date:  2021-12-23       Impact factor: 6.543

Review 8.  The Importance of Screening for Chagas Disease Against the Backdrop of Changing Epidemiology in the USA.

Authors:  Jennifer Ayres; Rachel Marcus; Claire J Standley
Journal:  Curr Trop Med Rep       Date:  2022-09-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.